We do know of serious risks — most
notably diabetes and obesity — associated with the long - term use of medications such as Risperdal, Seroquel, and Zyprexa.
Founded in 2015 after six years of work as part of the Enteroendocrine Discovery Performance Unit of GlaxoSmithKline, Phoundry Pharmaceuticals has created a portfolio of optimized peptides in various therapeutic categories, most
notably diabetes and obesity.